New Use for Active Ingredient of Cialis
June 4, 2009
Tadalafil, the Active Ingredient in ED Drug Cialis, Approved as Adcirca to Treat Pulmonary Arterial Hypertension
By Miranda Hitti WebMD Health News Reviewed by Louise Chang, MD
WASHINGTON (RPRN) 6/4/2009 -- The FDA has approved a new use for tadalafil, which is the active ingredient in the
erectile dysfunction drug Cialis. Tadalafil, sold as Adcirca, is now approved to improve exercise ability in people with
pulmonary arterial hypertension, which is a rare, life-threatening lung disorder that causes high
blood pressure in the lungs.
Adcirca comes in 40 milligram tablets; patients take one tablet per day.
In
2005, the FDA approved Revatio, a pulmonary arterial
hypertension drug made with sildenafil, the active ingredient in the erectile dysfunction drug Viagra. Revatio pills are taken three times daily at 20 milligrams per pill.
Adcirca, which will be available in August, is made by the drug company Lilly, which also makes Cialis. Adcirca will be marketed in the U.S. by United Therapeutics Corporation.
The FDA approved Adcirca based on a clinical trial in which pulmonary arterial hypertension patients either took Adcirca (given as two daily tablets, with each tablet containing 20 milligrams of tadalafil) or a placebo pill for 16 weeks.
At the end of the study, the patients walked for six minutes; during that time, patients taking Adcirca walked 33 meters farther than patients in the placebo group. Patients taking Adcirca also had less clinical worsening of their pulmonary arterial hypertension during the study than patients taking the placebo, according to a news release from United Therapeutics.
The most common side effects during the clinical trial included headache; muscle pain; flushing; colds and other respiratory tract infections; nausea; pain in the arms, legs, or back; upset stomach; and nasal congestion. United Therapeutics states that those side effects were generally brief and mild to moderate in intensity.
4 Must-See Articles
About the author: RushPRnews.com. Newswire. Read. Write. Publish. It's Your News.
Filed Under:
Health and Fitness, Lifestyle, FDA- Pharmaceutical news, Article-byline
RUSH PR NEWS newswire and press release services at rushprnews.com / Anne Howard annehowardpublicist.com
Content- Legal Responsibility - All material is copyrighted - You may repost but you MUST link back to the original post on your page and acknowledge Rush PR News as the news source. Rush PR News is not legally and/or morally responsible for content of press releases, opinions expressed or fact-checking.
Rush PR News cannot be held legally responsible for material published and distributed through its newswire service or published in its press-room and therefore cannot be sued for published material. Third-party must be contacted directly to dispute content.
Rush PR News is not the contact for material published.